OBJECTIVES: This study evaluates the budget impact of PCV 13 vaccination with free campaign for corporations, versus a hypothetical scenario where the corporation would pay campaign expenditures as proposed for PCV13 while vaccinating with PPV23. METHODS: A budget impact analysis was developed considering vaccination costs, campaign and associated health management costs, wage and productivity loss from employee absence due to sickness or death. Clinical events were calculated using a Markov model with individual-level simulation considering a cohort of 1.000.000 individuals of 60 years of age in a time horizon of 5 years, assuming a retirement age of 65. PCV effectiveness was extrapolated from infant results. Absence days due to health events were retrieved from national labor legislations.  Average wage was retrieved from the Brazilian Institute for Geography and Statistics (IBGE) 2012 data and productivity was estimated from the indicator ‘revenue generated by the employee’, from a market research developed by Exame magazine in 2012 using IBGE and the Brazilian Central Bank data. The base case considered a large corporation in Brazil with approximately 4000 eligible individuals. Values were expressed in 2012 USD. RESULTS: Independent campaign with  PPV23 and PCV13 vaccination plus free campaign totaled US$40.62 and US$61.40 per employee respectively. Productivity loss due to sick leave and death was US$709.61 and US$640.80 for PPV23 and PCV13 per employee, respectively. Considering all evaluated costs per employee and the number of eligible individuals, PPV23 and PCV13 totaled US$3,000,901.79 and US$2.808.787,58, respectively, representing US$192,114.21 of total savings for PCV13 vaccination when compared to PPV23. CONCLUSIONS: PCV13 vaccination with free campaign is estimated to save costs to employers, when compared to developing an independent campaign, mainly driven by productivity loss due to sick leave and death, which represented 112,07% of the total investment in a time horizon of 5 years.